Last reviewed · How we verify

NCT06197659

Effect of Liberal and Restrictive Fluids on Nausea-vomiting

Completed NA Last updated 16 February 2024
What this trial tests

NA trial testing Liberal Fluid Grubu in Postoperative Nausea and Vomiting in 160 participants. Completed in 15 February 2024.

Timeline
1 January 2024
Primary endpoint
10 February 2024
15 February 2024

Quick facts

Lead sponsorKaraman Training and Research Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment160
Start date1 January 2024
Primary completion10 February 2024
Estimated completion15 February 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Karaman Training and Research Hospital

Who can join

Adults 18 to 65, any sex, with Postoperative Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients planned for laparoscopic cholecystectomy will be included in this study. The effects of liberal and restrictive fluid regimens given peroperatively to patients undergoing laparoscopic cholecystectomy will be compared on postoperative nausea and vomiting. The aim of this study is to investigate which regimen is more effective on postoperative nausea and vomiting in laparoscopic cholecystectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Postoperative Nausea and Vomiting

Currently open trials in the same condition.

Other Karaman Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06197659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing